William Hornebeck

William Hornebeck

Auto-generated profile, based on publicly available information

William Hornebeck

Univ Reims, CNRS UMR 6237, Lab Biochim Med, Fac Med,Biomol IFR53, F-51096 Reims, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
WHWilliam Hornebeck
William Hornebeck
HEHervé Emonard
Hervé Emonard
JMJean-Claude Monboisse
Jean-Claude Monboisse
GBGeorges Bellon
Georges Bellon


1 March 2005 in Biochimie
Verified
Journal Article
Closed access
WHWilliam Hornebeck
William Hornebeck
ELElise Lambert
Elise Lambert
EPEmmanuelle Petitfrère
Emmanuelle Petitfrère
PBPhilippe Bernard
Philippe Bernard

10 September 2009 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
FAFrank Antonicelli
Frank Antonicelli
GBGeorges Bellon
Georges Bellon
SLSandrine Lorimier
Sandrine Lorimier
WHWilliam Hornebeck
William Hornebeck

1 January 2011 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Closed access
WHWilliam Hornebeck
William Hornebeck
HEHerve Emonard
Herve Emonard
Human elastases have been identified within serine, cysteine and metallopeptidase families. These enzymes are able to adsorb rapidly onto elastin, but they can also bind onto cell surface-associated proteins such as heparan sulfate proteoglycans, both interactions involving enzyme exosites distinct form active site. Immobilization of elastin at the cell surface will create a sequestered microenvironment and will favour elastolysis. Generated elastin peptides are potent matrikines displaying dual biological functions in physiopathology that are described in this review. Among properties, they are potent inducers of protease expression catalyzing collagenolysis or amplifying elastin degradation. The ability of unsaturated fatty acids and heparin(s) to control elastases action are delineated.

1 March 1999 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MPMyriam Polette
Myriam Polette
EHEric Huet
Eric Huet
PBPhilippe Birembaut
Philippe Birembaut
WHWilliam Hornebeck
William Hornebeck
FMFrançois‐Xavier Maquart
François‐Xavier Maquart
HEHervé Emonard
Hervé Emonard
Invasiveness and metastatic capacity of tumor cells have been related to increased expression and activation of gelatinase‐A (MMP‐2). 9‐octadecenoic acid (oleic acid, OA), a long‐chain cis‐unsaturated fatty acid, has been shown to partially inhibit the formation of lung metastatic colonies in an ex vivo model of implantation of metastatic cells into nude mice. Reduction of metastasis formation was suggested to be due to a decrease of MMP‐2 activity in tumor tissue extracts. Since regulation of MMP‐2 activity occurs at different levels, including gene expression, pro‐enzyme activation and finally active enzyme inhibition, we here investigated the precise level of the inhibitory effect of OA on MMP‐2 activity by oncogene‐transformed human bronchial epithelial cells (BZR cells). OA, at the dose of 5 × 10−5 M, was shown to inhibit by 50% MMP‐2 activity released from BZR cells. Northern‐blot analysis of mRNA encoding MMP‐2, MT1‐MMP, the physiological activator of MMP‐2, and TIMP‐2, the natural inhibitor of MMP‐2, revealed that OA did not alter the steady‐state levels of MMP‐2, MT1‐MMP and TIMP‐2 mRNA. Also, gelatin zymography demonstrated that the extent of MMP‐2 activation was not modified by OA treatment. On the contrary, OA could inhibit the fluorogenic quenching substrate (7‐methoxycoumarin‐4‐yl)acetyl‐L‐Pro‐Leu‐Gly‐Leu‐[N‐3‐(2,4‐dinitrophenyl)‐L‐2, 3‐diaminopropionyl]‐Ala‐Arg‐NH2 (Mca‐Pro‐Leu‐Gly‐Leu‐Dpa‐Ala‐Arg‐NH2) hydrolysis by recombinant MMP‐2 with Ki = 4.3 μM. These data suggest that the beneficial influence of OA on the formation of lung metastatic colonies was independent of its influence on MMP‐2 expression and/or activation, but could be attributed to inhibition of MMP‐2 activity. Int. J. Cancer 80:751–755, 1999.